Logo Image
Feature|Videos|May 4, 2026 (Updated: May 4, 2026)

Choosing the Right CDMO for Long-Term Stability

Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, outlines the deciding factors biotechs should consider when selecting a contract development and manufacturing organization (CDMO) partner.

Key Objectives

  • Identify the criteria biotech companies should evaluate when selecting a CDMO partner.
  • Learn why a CDMO's commercialization track record and technical expertise are critical factors in supporting complex biologic molecules through the full project lifecycle.
  • Recognize how CDMO size, client engagement practices, and supply chain reliability can influence the overall success of a drug development program.

Sponsored by Rentschler Biopharma

Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma, explores what biotech companies should prioritize when evaluating a CDMO partnership. He emphasizes that the decision carries long-term consequences given projects typically span many years. Key criteria discussed include transparent communication, accurate timelines, and a proven track record of guiding complex molecules through to commercialization. Also, he addresses the importance of technical expertise and supply chain reliability, noting that not all CDMOs are equipped to handle challenging molecules from the outset. Company stability, organizational size, and the depth of client engagement can factor into a biotech's selection process.

Related Content